Evidence map›Paper›PMID 41358253›Full record

ArticleWellcome open research2024

Neuroblastoma cell lines display heterogeneity in differentiation responses.

Kirsty M Ferguson, Sarah L Gillen, Fiona M Y Abou Grealy, Aditi Vedi, Anna Philpott

Abstract read
In one paragraph

Article in Wellcome open research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kirsty M FergusonJeffrey Cheah Biomedical Centre, Cambridge Stem Cell Institute, Cambridge, England, CB2 0AW, UK.ORCID https://orcid.org/0000-0002-6738-5203
Sarah L GillenJeffrey Cheah Biomedical Centre, Cambridge Stem Cell Institute, Cambridge, England, CB2 0AW, UK.
Fiona M Y Abou GrealyJeffrey Cheah Biomedical Centre, Cambridge Stem Cell Institute, Cambridge, England, CB2 0AW, UK.ORCID https://orcid.org/0009-0004-5316-4030
Aditi VediCambridge University Hospitals NHS Foundation Trust, Cambridge, England, UK.
Anna PhilpottJeffrey Cheah Biomedical Centre, Cambridge Stem Cell Institute, Cambridge, England, CB2 0AW, UK.

Funding

Wellcome Trust
6 · The paper itself

Abstract

Background: Neuroblastoma is the most common extra-cranial childhood solid tumour, arising during development from stalled neural crest-derived precursor cells. In a subset of children younger than 18 months of age, neuroblastoma can undergo spontaneous regression driven by differentiation, leading to great interest in developing differentiation therapies to re-direct neuroblastoma cells down their correct developmental pathway. Recently, we have shown that combinatorial treatment with the CDK4/6 inhibitor palbociclib and differentiation-inducing agent retinoic acid inhibits proliferation and drives neuronal differentiation of adrenergic-type neuroblastoma cell lines. Methods: Here, we explore the differentiation potential of neuroblastoma cell lines Results: We present evidence suggesting that neuroblastoma cells can give rise to mixtures of neural crest-derived adrenal gland cell types, and that differentiation responses correspond to changes in patterns of extracellular matrix substrate expression. Conclusions: This study builds a case to further investigate and consider heterogeneity in neuroblastoma cell differentiation and extracellular matrix changes during these cell fate decisions.

Indexed as

differentiationextracellular matrixneural crestneuroblastomapalbociclibretinoic acid

Identifiers

PMID41358253
PMCPMC12676116

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.